Canaan-Backed Biotech Gives Orphan Receptor a Home and New Role in Gut Cancer Drugs
ThirtyFiveBio aims to treat gastrointestinal cancer by targeting a so-called orphan receptor called GPR35. The biotech startup is revealing its science at the American Association of Cancer Research annual meeting.